<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940184</url>
  </required_header>
  <id_info>
    <org_study_id>UC/RH-vago-GLP-1</org_study_id>
    <nct_id>NCT02940184</nct_id>
  </id_info>
  <brief_title>GLP-1 Signaling in Truncally Vagotomized Subjects</brief_title>
  <official_title>Vagal Mechanisms Mediating the Effects of Glucagon-Like Peptide 1 (GLP-1) on the Endocrine Pancreas - the Entero-endocrine Axis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of the importance of vagal signaling for the glucohomeostatic effects of GLP-1.
      The study will include physiological studies of truncally vagotomized participants and
      matched controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>up to 4 hours</time_frame>
    <description>Evaluated by c-peptide and insulin levels - Plasma collected up to 4 hours will be analyzed for peptide hormones</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon secretion</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma collected over 4 hours will be analyzed for peptide hormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose levels</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma collected over 4 hours will be analyzed for glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic Polypeptide levels</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma collected over 4 hours will be analyzed for peptide hormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP secretion</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma collected over 4 hours will be analyzed for peptide hormones</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Physiology</condition>
  <arm_group>
    <arm_group_label>Enteral fructose with DPP-4 inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enteral fructose + DPP-4 inhibition (sitagliptin)
After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enteral fructose without DPP-4 inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enteral fructose without DPP-4 inhibition (sitagliptin) After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tablet Sitagliptin 100mg (evening before and morning of experiments)</intervention_name>
    <description>On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).</description>
    <arm_group_label>Enteral fructose with DPP-4 inhibition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intestinal Fructose administration</intervention_name>
    <description>On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube</description>
    <arm_group_label>Enteral fructose with DPP-4 inhibition</arm_group_label>
    <arm_group_label>Enteral fructose without DPP-4 inhibition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Truncally vagotomized individuals:

        Inclusion Criteria:

          -  Normal fasting plasma glucose

          -  Normal haemoglobin concentration

          -  Cardiaresection with a pyloroplasty

          -  Informed consent

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Disposition for diabetes mellitus

          -  Intestinal disease (apart from cardia resection+pyloroplasty)

          -  Disposition of inflammatory bowel disease

          -  Intestinal resection (apart from cardia resection+pyloroplasty)

          -  Body mass index (BMI) &gt; 27,5 kg/m2

          -  Tobacco use

          -  Nephropathy (se-creatinine&gt; 130 µM and/or albuminuria)

          -  Liver disease (ALAT and/or ASAT &gt;2 × refference value)

          -  known heart condition

          -  medicinal use, that may not be paused for 12 hours

          -  Obstipation

          -  swallowing difficulties

          -  previous problems with intestinal tube placement

          -  Latex allergy

          -  Fructose malabsorption

          -  Known diseases in the pharynx

          -  Previous facial or cranial fractures

          -  Sinusitis

          -  Bleeding diathesis

        Matched controls:

        Inclusion Criteria:

          -  Normal fasting plasma glucose

          -  Normal haemoglobin concentration

          -  Informed consent

        Exclusion Criteria:

          -  Cardiaresection with a pyloroplasty

          -  Diabetes mellitus

          -  Disposition for diabetes mellitus

          -  Intestinal disease (apart from cardia resection+pyloroplasty)

          -  Disposition of inflammatory bowel disease

          -  Intestinal resection tarmresektion (apart from cardia resection+pyloroplasty)

          -  Body mass index (BMI) &gt; 27,5 kg/m2

          -  Tobacco use

          -  Nephropathy (se-creatinine&gt; 130 µM and/or albuminuria)

          -  Liver disease (ALAT and/or ASAT &gt;2 × refference value)

          -  known heart condition

          -  medicinal use, that may not be paused for 12 hours

          -  Obstipation

          -  swallowing difficulties

          -  previous problems with intestinal tube placement

          -  Latex allergy

          -  Fructose malabsorption

          -  Known diseases in the pharynx

          -  Previous facial or cranial fractures

          -  Sinusitis

          -  Bleeding diathesis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Surgery C, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Veedfald, MD</last_name>
      <phone>+45 41 10 25 95</phone>
    </contact>
    <contact_backup>
      <last_name>Lars Bo Svendsen, Dr.Med.Sci</last_name>
      <phone>+45 35 45 21 22</phone>
      <email>Lars.Bo.Svendsen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Veedfald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>May 20, 2018</last_update_submitted>
  <last_update_submitted_qc>May 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Simon Veedfald</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Physiology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

